Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency

被引:18
作者
Abrahamsen, B
Nielsen, TL
Hangaard, J
Gregersen, G
Vahl, N
Korsholm, L
Hansen, TB
Andersen, M
Hagen, C
机构
[1] Odense Univ Hosp, Dept Endocrinol M, DK-5000 Odense C, Denmark
[2] Ribe Cty Hosp, Dept Med, DK-6700 Esbjerg, Denmark
[3] Aarhus Kommune Hosp, Dept Med Endocrinol M, Aarhus, Denmark
[4] Univ So Denmark, Dept Stat, Odense, Denmark
关键词
D O I
10.1530/eje.0.1500671
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Patients with GH deficiency of adult onset (GHDA) exhibit dyslipidacmia and increased cardiovascular morbidity GH replacement potently reduces body fat and serum lipids in GHDA. In recent years, lower GH doses have been introduced. The purpose of this analysis was to explore the response relationship between GH doses. lipids and body composition. Design: Two consecutive, randomized 12-month GH replacement studies covering placebo and three different doses of GH (0.5. 1.0 and 1. 7 IU/m(2) per day). Low and intermediate doses were IGF-I titrated. Patients: Fifty-eight patients with severe GHDA. not previously treated with GH and stably substituted for other endocrine deficiencies, were included in the study. methods: Serum lipoproteins. serum IGF-I and body composition analysis by dual energy X-ray absorptiometry (DXA) were used. Results: Fifty-seven percent of patients exhibited low density lipoprotein (LDL) cholesterol levels above 4.16 mmol/l, corresponding to the American Heart Association threshold of 160 mg/dI. GH treatment resulted in significant decreases in total and LDL cholesterol, with no significant change in high density lipoprotein cholesterol or triglycerides. The low dose induced no significant changes in lipid levels, whereas the medium dose reduced LDL cholesterol and the high dose decreased both LDL and total cholesterol. The effects depended significantly on the GH dose and the level of IGF-I obtained. but not on gender. GH replacement induced dose-dependent reductions in fat mass and sex-dependent increases in lean mass. Conclusions: GH given for I year at a dosage between 0.5 and 1.7 IU/m(2) per day reduced fat mass in a dose-dependent manner. increased lean body mass and lowered total and LDL cholesterol in patients with severe GHDA. Low dose GH treatment with normal IGF-I levels induced smaller changes compared with high dose therapy and may need a longer treatment time.
引用
收藏
页码:671 / 679
页数:9
相关论文
共 38 条
[1]  
Andersen M., 1996, ENDOCRINOL METAB, V3, P197
[2]  
[Anonymous], 2000, Ethical Principles for Medical Research Involving Human Subjects
[3]   LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy [J].
Arosio, M ;
Sartore, G ;
Rossi, CM ;
Casati, G ;
Faglia, G ;
Manzato, E .
ATHEROSCLEROSIS, 2000, 151 (02) :551-557
[4]  
Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
[5]   TREATMENT OF ADULTS WITH GROWTH-HORMONE (GH) DEFICIENCY WITH RECOMBINANT HUMAN GH [J].
BENGTSSON, BA ;
EDEN, S ;
LONN, L ;
KVIST, H ;
STOKLAND, A ;
LINDSTEDT, G ;
BOSAEUS, I ;
TOLLI, J ;
SJOSTROM, L ;
ISAKSSON, OGP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (02) :309-317
[6]   THE EFFECTS OF SHORT AND LONG-TERM GROWTH-HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS ON LIPID-METABOLISM AND CARBOHYDRATE-TOLERANCE [J].
BESHYAH, SA ;
HENDERSON, A ;
NITHTHYANANTHAN, R ;
SKINNER, E ;
ANYAOKU, V ;
RICHMOND, W ;
SHARP, P ;
JOHNSTON, DG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (02) :356-363
[7]   Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review [J].
Carroll, PV ;
Christ, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) :382-395
[8]   Dyslipidaemia in adult growth hormone (GH) deficiency and the effect of GH replacement therapy: A review [J].
Christ, ER ;
Cummings, MH ;
Russell-Jones, DL .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (05) :200-206
[9]   Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance [J].
Colao, A ;
Cuocolo, A ;
Marzullo, P ;
Nicolai, E ;
Ferone, D ;
Morte, AMD ;
Pivonello, R ;
Salvatore, M ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1551-1557
[10]   The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults [J].
Cuneo, RC ;
Judd, S ;
Wallace, JD ;
Perry-Keene, D ;
Burger, H ;
Lim-Tio, S ;
Strauss, B ;
Stockigt, J ;
Topliss, D ;
Alford, F ;
Hew, L ;
Bode, H ;
Conway, A ;
Handelsman, D ;
Dunn, S ;
Boyages, S ;
Cheung, NW ;
Hurley, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :107-116